Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program

被引：0
|
作者：
Vermeire, Severine [1 ]
Rubin, David T. [2 ]
Peyrin-Biroulet, Laurent [3 ,4 ]
Dubinsky, Marla C. [5 ]
Regueiro, Miguel [6 ]
Irving, Peter M. [7 ]
Goetsch, Martina [8 ]
Lazin, Krisztina [8 ]
Wu, Joseph [9 ]
Modesto, Irene [10 ]
Woolcott, John C. [11 ]
McDonnell, Aoibhinn [12 ]
Rabbat, Christopher J. [10 ]
Yarur, Andres J. [13 ]
机构：
[1] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium
[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[3] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France
[4] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France
[5] Mt Sinai Kravis Childrens Hosp, New York, NY USA
[6] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH USA
[7] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England
[8] Pfizer AG, Zurich, Switzerland
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Inc, New York, NY USA
[11] Pfizer Inc, Collegeville, PA USA
[12] Pfizer Ltd, Sandwich, Kent, England
[13] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S905
引用
收藏
页码：S675 / S675
页数：1
相关论文
共 50 条
  • [41] Real-world Effectiveness and Tolerability of Etrasimod in Active Ulcerative Colitis: A 26-week Observational Study
    St-Pierre, J.
    Choi, D.
    Yanofsky, R.
    Fear, E.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1540 - i1540
  • [42] Matching-Adjusted Indirect Comparison of Etrasimod Versus Ozanimod for Clinical Response and Remission Among Patients With Moderately to Severely Active Ulcerative Colitis
    Jairath, Vipul
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1058 - S1059
  • [43] Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
    Jairath, Vipul
    Raine, Tim
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025, 14 (04)
  • [44] Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
    Danese, Silvio
    Komori, H. Kiyomi
    Ryan, Rathi D.
    Cataldi, Fabio
    Lee, Caroline A.
    Goetsch, Martina
    Siegmund, Britta
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S673 - S673
  • [45] ETRASIMOD ASSOCIATED BRADYCARDIA WITH UNPRECEDENTED HEART RATE BELOW 40BPM IN MODERATELY SEVERE ULCERATIVE COLITIS: A CASE REPORT
    EL-Najjar, Yassin
    Touma, Mary-Joe
    Cordova, Noelle
    Fudman, David
    Boktor, Moheb
    INFLAMMATORY BOWEL DISEASES, 2025, 31 : S1 - S2
  • [46] CORRELATION OF FECAL CALPROTECTIN AND C-REACTIVE PROTEIN CONCENTRATIONS WITH CLINICAL OUTCOMES AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING INDUCTION THERAPY WITH ETRASIMOD
    Yarur, Andres J.
    Jairath, Vipul
    Zhang, Jinkun
    Panes, Julian
    Chiorean, Michael V.
    Peyrin-Biroulet, Laurent
    Vermeire, Severine
    Cabell, Chris
    Naik, Snehal
    Sandborn, William J.
    GASTROENTEROLOGY, 2019, 156 (06) : S1108 - S1109
  • [47] Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12
    Armuzzi, Alessandro
    Rubin, David T.
    Schreiber, Stefan
    Panes, Julian
    Fellmann, Marc
    Bartolome, Lauren
    Gruben, David
    Goetsch, Martina
    Bhattacharjee, Abhishek
    Chaparro, Maria
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [48] THE EFFECT OF ETRASIMOD ON FECAL CALPROTECTIN AND HIGHSENSITIVITY C-REACTIVE PROTEIN: RESULTS FROM THE ELEVATE UC CLINICAL PROGRAM
    Jairath, Vipul
    Rubin, David T.
    Verstockt, Bram
    Cekin, Ayhan Hilmi
    Abreu, Maria T.
    Lees, Charlie W.
    Fellmann, Marc
    Woolcott, John
    Crosby, Catherine
    Wu, Joseph
    Bhattacharjee, Abhishek
    Herman, David
    Gu, Guibao
    Siegmund, Britta
    GASTROENTEROLOGY, 2024, 166 (05) : S816 - S816
  • [49] Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial
    Yarur, Andres J.
    Chiorean, Michael, V
    Panes, Julian
    Jairath, Vipul
    Zhang, Jinkun
    Rabbat, Christopher J.
    Sandborn, William J.
    Vermeire, Severine
    Peyrin-Biroulet, Laurent
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (06): : 885 - 894
  • [50] Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
    Chaparro, M.
    Armuzzi, A.
    Irving, P. M.
    Allez, M.
    Dubinsky, M. C.
    Sands, B. E.
    Goetsch, M.
    Wang, W.
    Shan, K.
    Woolcott, J.
    Bartolome, L.
    Wosik, K.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I107 - I110
12345